SML2260
Taspoglutide trifluoroacetate salt
≥95% (HPLC)
동의어(들):
8-(2-Methylalanine)-35-(2-methylalanine)-36-L-argininamide-7-36-glucagon-like peptide I (human) trifluoroacetate salt, BIM 51077 trifluoroacetate salt, R1583 trifluoroacetate salt, RO 5073031 trifluoroacetate salt, [Aib8,35]hGLP-1(7-36)NH2; H-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2 trifluoroacetate salt
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
5 MG
₩124,033
25 MG
₩498,974
About This Item
실험식(Hill 표기법):
C152H232N40O45 · xC2HF3O2
CAS Number:
Molecular Weight:
3339.71 (free base basis)
UNSPSC 코드:
51111800
NACRES:
NA.77
추천 제품
분석
≥95% (HPLC)
양식
lyophilized powder
색상
white to beige
배송 상태
wet ice
저장 온도
−20°C
관련 카테고리
생화학적/생리학적 작용
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist. Taspoglutide improves glucose tolerance, postprandial glucose, body weight, glycaemic control and insulin sensitivity in the Zucker diabetic fatty rat.
long-acting glucagon-like peptide 1 (GLP-1) receptor agonist
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Lot/Batch Number
S R K Seshasai et al.
Diabetes, obesity & metabolism, 17(5), 505-510 (2015-02-07)
To study the short-term cardiovascular effects of the once-weekly glucagon-like peptide-1 receptor agonist taspoglutide. We conducted a meta-analysis of individual-participant data from nine randomized controlled trials in the T-Emerge programme, which assessed the efficacy and safety of taspoglutide in type
E Sebokova et al.
Diabetes, obesity & metabolism, 12(8), 674-682 (2010-07-02)
Glucagon-like peptide-1 (GLP-1) receptor agonists are a novel class of pharmacotherapy for type 2 diabetes. We investigated the effects of a novel, long-acting human GLP-1 analogue, taspoglutide, in the Zucker diabetic fatty (ZDF) rat, an animal model of type 2
K Pabreja et al.
British journal of pharmacology, 171(5), 1114-1128 (2013-07-31)
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
